Track market-moving stories before they get noisy

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation ("Neogen" or the "Company") (NASDAQ: NEOG).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

The growing importance of food safety, agricultural traceability and product verification creates business opportunities for Neogen Corporation (NEOG - Free Report) and Where Food Comes From, Inc. (WFCF - Free Report) . Although both companies serve the broader food industry, their business models differ. Neogen provides food and animal safety testing products and solutions, while Where Food Comes From specializes in independent verification, certification and traceability services across agricultural supply chains.

The Case for NEOGAccelerating Core Revenue Growth: Neogen reported first-quarter fiscal 2027 revenues of $222.8 million, up 6.5% year over year, with core growth of 8.1%. Food Safety revenues increased 7.4% to $163.2 million, supported by an 11% increase in indicator testing and culture media products, including Petrifilm, and 7% growth in bacterial and general sanitation products.

Animal Safety revenues rose 4.2% to $59.6 million, benefiting from improved veterinary instrument supplies and the demand for insect control products. However, approximately 300 basis points of companywide core growth reflected favorable order timing and prior-year distributor inventory adjustments. This suggests that the underlying growth trajectory is more moderate than the headline figure.

Improving Operating Performance: NEOG's adjusted EBITDA increased to $41.6 million in the first quarter of fiscal 2027 from $35.5 million a year earlier, while its adjusted EBITDA margin expanded 170 basis points to 18.7%. Adjusted operating income rose to $36.5 million from $29.6 million, supported by higher revenues and operating leverage.

Free cash flow improved to $4.7 million from negative $13.1 million in the prior-year quarter, partly reflecting a $16-million reduction in capital expenditure. These improvements indicate progress in financial execution, although the company recorded a net loss of $11.9 million, highlighting the continuing gap between adjusted profitability and reported earnings.

Petrifilm Transition & Innovation Opportunities: Neogen completed validation of its first Petrifilm stock-keeping unit in August 2026 and expects to begin the planned multi-quarter manufacturing transition to its Lansing facility in November 2026. This represents an important step toward completing the integration of the former 3M Food Safety business and potentially improving manufacturing efficiency and supply reliability.

In October 2026, NEOG also announced a collaboration and equity investment in Hinalea Imaging Corp. to develop hyperspectral imaging solutions for food safety inspection. These initiatives could strengthen the product portfolio over time, although their financial contributions remain dependent on successful commercialization and execution.

Raised Guidance Supports Growth Prospects: Following its first-quarter performance, Neogen raised the fiscal 2027 revenue guidance to $885-$890 million from $880-$885 million and the adjusted EBITDA guidance to $181-$183 million from $180-$182 million. Management expects first-half core revenue growth of 3.5%, with the second quarter likely to record the weakest growth rate of the fiscal year.

The company is also increasing investments in research and development, commercial capabilities and enterprise systems. These initiatives support longer-term opportunities, although their near-term costs may limit margin expansion.

The Case for WFCFExpanding Certification Portfolio: Where Food Comes From continues to diversify beyond its traditional beef verification business. The company provides auditing services covering more than 50 standards, including animal welfare, organic, non-GMO, gluten-free and sustainability certifications. Its RaiseWell Certified program, adopted by Whole Foods Market for beef supply certification in the first quarter of 2026, had enrolled more than 270,000 head of cattle by August 2026.

WFCF also intends to expand RaiseWell into chicken, turkey, pork, lamb and eggs. Additionally, its partnership with the Potato Sustainability Alliance creates opportunities in agricultural sustainability audits. These initiatives could support revenue diversification and strengthen customer relationships, although the timing and scale of future contributions remain uncertain.

Expanding Operating Margins: WFCF reported second-quarter 2026 revenues of $6.61 million, up approximately 1% year over year. Despite modest top-line growth, gross profit increased 9% to $2.68 million, with the gross margin expanding to 40.6% from 37.5%, reflecting cost efficiencies across all three revenue streams. Operating income increased 21% to $665,000 from $549,000.

For the first six months of 2026, operating income rose 39% year over year to $963,000, although the improvement also benefited from a roughly $400,000 compensation-related adjustment in the first quarter. These results indicate improved operating efficiency, but the sustainability of margin gains will depend on expense discipline and stronger revenue generation.

Conservative Balance Sheet & Shareholder Returns: WFCF ended June 2026 with cash and cash equivalents of $3.42 million compared with $3.20 million at 2025-end, and had minimal finance lease obligations. The operating cash flow totaled $1.46 million in the first half of 2026, compared with $1.81 million in the prior-year period.

The company repurchased 89,481 shares during the first six months, including 65,012 shares for approximately $809,000 in the second quarter. Since 2019, WFCF has returned $17.2 million to shareholders through buybacks and a special dividend. Its limited financial debt and history of capital returns provide flexibility, although lower operating cash generation warrants monitoring.

Renewed Acquisition Strategy:WFCF is exploring acquisition opportunities after approximately three years without a transaction. Management highlighted its historical approach of acquiring complementary certification capabilities, customers and revenue streams, with an emphasis on transactions that could become immediately or near-term accretive.

In August 2026, the company outlined plans to file a shelf registration statement to provide financing flexibility for potential acquisitions. This renewed focus could support expansion into additional verification markets and reduce the reliance on the cattle industry.

Challenges Facing NEOG & WFCFNEOG's Debt & Integration Risks: Neogen had approximately $774 million in total debt and $172 million in cash as of Aug. 31, 2026, resulting in net debt of about $602 million. The company repaid $20 million of its term loan in June and another $10 million in September. Its proposed sale of the Genomics business to Zoetis is expected to generate $140 million in net proceeds, primarily for debt reduction, subject to regulatory reviews expected to conclude by December 2026.

Management anticipates net leverage falling below 3 times at closing and approaching 2.5 times by the end of the fiscal year. However, delays in the divestiture or the Petrifilm manufacturing transition could slow deleveraging and operational improvement. Continued spending on innovation and technology also creates near-term profitability considerations.

WFCF's Limited Revenue Growth & Beef Exposure: Where Food Comes From remains exposed to challenging conditions in the U.S. cattle industry, including historically low herd sizes and elevated beef prices. Management indicated in August 2026 that beef-related operations accounted for roughly 50% of revenues, making industry conditions significant to overall performance.

First-half 2026 revenues inched up 1.2% to $11.98 million, while verification and certification revenues rose 3.1% to $9.81 million. Professional services revenues declined to $513,000 from $655,000. Although new programs are helping diversify the business, their expansion has yet to generate substantial consolidated revenue growth. First-half net income declined to $505,000 from $593,000, partly reflecting a $299,000 adverse year-over-year swing in digital-asset valuations.

Which Stock Has the Edge?NEOG has the edge in growth and operational improvement potential, supported by stronger demand across its two business segments, improving adjusted profitability, increased fiscal 2027 guidance and opportunities associated with the Petrifilm manufacturing transition. The expected Genomics divestiture could also improve financial flexibility by reducing leverage. Nevertheless, its investment case requires continued execution, particularly as the company works to convert adjusted operating gains into sustained profitability and free cash flow.

WFCF has the edge in balance-sheet conservatism and current profitability. Its diversified certification offerings, improving gross margin and disciplined approach to capital allocation support a comparatively less debt-dependent operating model. However, slow revenue growth, substantial beef-industry exposure and limited visibility into the financial contribution of newer programs constrain its near-term growth outlook.

Overall, NEOG appears better-positioned for investors prioritizing revenue growth and potential operating recovery, while WFCF offers a more conservative financial profile. NEOG's stronger growth comes with greater debt and execution risks, whereas WFCF's lower leverage is offset by its more modest business expansion.

BENSALEM, Pa. , Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEOGEN CORPORATION (NEOG), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?
On September 29, 2026, the FDA announced it had issued a warning letter to Neogen, following an investigation that linked a Neogen’s Hycoat product “to serious infections and deaths in horses.” The FDA stated the “incident involved at least 20 horse deaths, making it the largest number of horse deaths ever associated with a quality defect in an FDA-regulated veterinary medical product and the most deaths of any animal species linked to microbiological contamination of an FDA-regulated product labeled as sterile.” The FDA also reviewed Hycoat’s labeling and determined that the product is also misbranded “because its labeling fails to bear adequate directions for use.”

On this news, Neogen stock fell $0.99 or 7.22%, to close at $12.73 on September 29, 2026.

Contact Us To Participate or Learn More:
If you purchased Neogen Corporation securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON NEOGEN CORPORATION (NEOG), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?
On September 29, 2026, the FDA announced it had issued a warning letter to Neogen, following an investigation that linked a Neogen’s Hycoat product “to serious infections and deaths in horses.” The FDA stated the “incident involved at least 20 horse deaths, making it the largest number of horse deaths ever associated with a quality defect in an FDA-regulated veterinary medical product and the most deaths of any animal species linked to microbiological contamination of an FDA-regulated product labeled as sterile. The FDA also reviewed Hycoat’s labeling and determined that the product is also misbranded “because its labeling fails to bear adequate directions for use.”

On this news, Neogen stock fell $0.99 or 7.22%, to close at $12.73 on September 29, 2026.

Contact Us To Participate or Learn More:
If you purchased Neogen Corporation securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [email protected]
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz
310-914-5007
[email protected]
www.frankcruzlaw.com

Neogen Corporation (NASDAQ:NEOG – Get Free Report) has been assigned a consensus recommendation of “Hold” from the five analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $12.67.

NEOG has been the subject of a number of research reports. Weiss Ratings raised shares of Neogen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. Wall Street Zen downgraded Neogen from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Guggenheim reaffirmed a “buy” rating and issued a $14.00 target price (up from $12.00) on shares of Neogen in a research note on Wednesday, September 30th. Finally, Piper Sandler upgraded shares of Neogen from a “neutral” rating to an “overweight” rating and increased their price target for the company from $13.00 to $14.00 in a research report on Wednesday, August 26th.

Get Our Latest Analysis on NEOG

Institutional Investors Weigh In On Neogen A number of institutional investors have recently made changes to their positions in NEOG. Farther Finance Advisors LLC raised its position in Neogen by 76.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,184 shares of the company’s stock worth $28,000 after purchasing an additional 944 shares during the period. Nykredit A S bought a new stake in Neogen in the second quarter worth $28,000. Public Employees Retirement System of Ohio bought a new stake in Neogen in the second quarter worth $34,000. Integrated Wealth Concepts LLC purchased a new stake in Neogen during the second quarter valued at about $73,000. Finally, Plan A Wealth LLC purchased a new stake in Neogen during the third quarter valued at about $133,000. Hedge funds and other institutional investors own 96.73% of the company’s stock. Neogen Stock Performance NASDAQ:NEOG opened at $11.85 on Friday. The stock has a market cap of $2.59 billion, a P/E ratio of -47.40, a PEG ratio of 4.44 and a beta of 1.79. The company has a quick ratio of 2.92, a current ratio of 3.90 and a debt-to-equity ratio of 0.37. The business’s 50-day moving average price is $12.12 and its two-hundred day moving average price is $10.31. Neogen has a twelve month low of $5.37 and a twelve month high of $14.26.

Neogen (NASDAQ:NEOG – Get Free Report) last issued its quarterly earnings data on Tuesday, October 6th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.05 by $0.03. The company had revenue of $222.80 million during the quarter, compared to analyst estimates of $208.18 million. Neogen had a positive return on equity of 3.29% and a negative net margin of 6.35%. Neogen’s revenue was up 6.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.04 earnings per share. As a group, equities analysts predict that Neogen will post 0.27 EPS for the current fiscal year.

Key Headlines Impacting Neogen Here are the key news stories impacting Neogen this week:

Positive Sentiment: Strong quarterly results and higher guidance: Neogen reported fiscal first-quarter revenue of $222.8 million, up 6.5% year over year and above the $208.2 million consensus estimate. Adjusted earnings of $0.08 per share exceeded expectations by $0.03. Management also raised its fiscal 2027 outlook, supporting the recent increase in the stock. Neogen Q1 Revenue Rises 6.5%; Raises FY27 Outlook Positive Sentiment: Encouraging long-term targets: At its 2026 Investor Day, Neogen outlined plans for sustained growth, greater research and development investment, and expansion toward a 30% EBITDA margin by fiscal 2031. The focus on recurring food-safety demand and innovation strengthens the long-term investment thesis, although execution will be important. Neogen Outlines Strategy for Growth, Innovation and Margin Expansion Positive Sentiment: Analyst and industry support: Coverage has highlighted Neogen as a medical-products company positioned to benefit from favorable industry trends, while commentary on the earnings call described management as confident about its growth path. Medical Product Stocks Positioned to Ride on Industry Tailwinds Neutral Sentiment: Short-interest data is inconsistent: A report described a significant increase in short interest but listed total short interest of zero shares and a 0.0-day short ratio. This suggests no meaningful short-selling pressure, though the data should be treated cautiously. Negative Sentiment: FDA and legal overhang: Reports of an FDA warning related to a contaminated veterinary product could create compliance, reputation, or remediation costs. Separately, Pomerantz LLP announced an investigation into potential investor claims, adding headline and litigation risk. Neogen Received an FDA Warning About Neogen (Get Free Report)

Neogen Corporation is a global provider of food safety and animal safety products and services. The company develops diagnostic tests, laboratory products, and related solutions that help customers detect foodborne pathogens, allergens, toxins, residues, and other contaminants throughout the food production process.

Its food safety portfolio includes test kits, culture media, molecular testing systems, sanitation monitoring products, and laboratory supplies used by food manufacturers, processors, retailers, and regulatory organizations.

See Also Five stocks we like better than Neogen 3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip Home Depot and Lowe’s Hit 52-Week Lows—But Analysts Aren’t Giving Up Utilities Are Bouncing Back—These 2 Giants Could Signal the Next Big Sector Rally Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.

SummaryI believe Neogen’s recurring food safety products provide a foundation for its operating recovery.However, management has to execute carefully and proceed with the Petrifilm transition, which, if successful, should improve its cash flows long-term.Also, NEOG’s recent genomics sale should give it extra flexibility, but we have to wait and see until we know how much its earnings may decrease as a result.Still, on balance, I think that NEOG’s ongoing recovery remains a viable “Buy” at these levels for investors seeking exposure to food safety. AleksandarGeorgiev/E+ via Getty Images

Neogen Corporation (NEOG) offers testing technologies and consumable products to assist food producers, laboratories, and animal-health professionals. Their products are used for detecting contamination, checking quality, and protecting livestock, generally speaking. NEOG is also currently experiencing

3.65K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

LANSING, Mich.--(BUSINESS WIRE)--Neogen Corporation (NASDAQ: NEOG) today hosted its 2026 Investor Day, "Shaping the Future of Food Safety," in New York City, where the company's senior leadership team outlined a comprehensive strategy for sustained profitable growth and category leadership, and provided a framework under which it plans to achieve financial targets by fiscal year 2031. The event featured presentations from Mike Nassif, President and Chief Executive Officer; Bryan Riggsbee, Chief.

Neogen (NASDAQ:NEOG) reported fiscal 2027 first-quarter revenue of $222.8 million, with core growth of 8.1%, as the company cited improved commercial execution, product-line strength in food safety and animal safety, and progress on its Petrifilm manufacturing transition.

Chief Executive Officer Mike Nassif said the quarter marked an acceleration from the prior quarter, though he noted that the timing of certain customer orders contributed to growth. The company is focusing its fiscal 2027 strategy on commercial execution, innovation and operational efficiency while continuing investments intended to support long-term growth and profitability.

Revenue Growth Across Both Segments Food Safety revenue totaled $163.2 million, representing 8.1% core growth. Chief Financial Officer Bryan Riggsbee said first-quarter Food Safety growth received an approximately 400-basis-point benefit from order timing and a comparison to the prior-year period, when two large distributors made inventory adjustments. Within Food Safety, indicator testing and culture media products, including Petrifilm, increased 11%. Bacterial and general sanitation products grew 7%, including double-digit growth in pathogen detection, Riggsbee said.

Animal Safety revenue was $59.6 million and rose 8% on a core basis, including roughly a 100-basis-point benefit from the timing of customer orders. The segment’s growth was driven by veterinary instruments, including needles and syringes supported by improved supply, as well as biosecurity products, particularly insect-control offerings.

Neogen generated growth in each geographic region, led by double-digit growth in Asia-Pacific. U.S. sales represented 49% of quarterly revenue, while international markets accounted for 51%.

During the question-and-answer session, Chief Commercial Officer Joe Freels said the company is working to increase its share of wallet with existing customers rather than relying primarily on new markets. He highlighted a new approach for global strategic accounts, under which a dedicated accountable leader is assigned to individual customers operating across multiple regions. Freels said those accounts grew 6.2% in the first quarter.

Margins, Cash Flow and Debt Neogen reported gross margin of 47.4% and adjusted gross margin of 49.8%, up 30 basis points from a year earlier on an adjusted basis. The adjusted margin improvement reflected higher revenue, partially offset by deliberate investments in operational excellence and inventory optimization.

Adjusted operating expenses were approximately flat year over year. Increased investment in research and development and general and administrative functions was offset by lower sales and marketing costs, including lower logistics and distribution expenses, centralized regional marketing resources and the divestiture of the cleaners and disinfectants business.

Adjusted EBITDA was $41.6 million, or 18.7% of revenue, representing 170 basis points of margin expansion. Adjusted net income was $17.5 million, and adjusted earnings per share were $0.08.

Free cash flow was $4.7 million, improving approximately $18 million from the prior-year quarter. Riggsbee attributed the improvement to higher operating cash flow and reduced capital expenditures as the company approaches completion of the Petrifilm manufacturing transition.

Neogen ended the quarter with about $774 million in debt and $172 million in cash. The company repaid $20 million of its term loan in June and another $10 million at the end of September. It remains compliant with its debt covenants, Riggsbee said.

Petrifilm Transfer and Innovation Initiatives The company said its planned multi-quarter transfer of Petrifilm manufacturing is expected to begin next month. Neogen has completed full validation of its first Petrifilm stock-keeping unit, confirming that the product met production, quality and stability requirements and performed equivalently to product made by its transition partner.

Nassif called the validation a “major de-risking milestone” for the program. He said Neogen is managing the transition around four priorities: customer continuity, safety-stock management, supplier management and disciplined sequencing across 17 SKUs.

Riggsbee said duplicative costs related to the transition are expected to peak and then decline as the transfer is completed. He said the company expects to begin implementing identified operational improvements during fiscal 2028 and anticipates 200 to 300 basis points of margin improvement in fiscal 2029.

Neogen also announced a strategic collaboration with Hinalea, a hyperspectral imaging company. Nassif said the technology could have applications across Food Safety and may help simplify customer workflows through faster detection and decision-making at processing sites.

Guidance Raised; Genomics Sale Still Under Review Neogen raised its fiscal 2027 revenue outlook to $885 million to $890 million and increased adjusted EBITDA guidance to $181 million to $183 million. The guidance continues to include the genomics business, which Neogen has agreed to divest.

The genomics transaction remains under review by regulatory authorities in Australia and New Zealand, with a final decision expected by the end of December. Neogen expects approximately $140 million in net proceeds, primarily for debt reduction. Riggsbee said the sale could reduce net leverage to below three times at closing and closer to 2.5 times by the end of the fiscal year.

The company expects first-half core growth of approximately 3.5%, noting that first-quarter results benefited from timing items and that the second quarter is expected to have the lowest core growth rate of the year. Neogen expects first-half adjusted EBITDA margin to be in line with the first quarter while it continues to invest in R&D, commercial infrastructure, technology and automation.

About Neogen (NASDAQ:NEOG) Neogen Corporation is a global provider of food safety and animal safety products and services. The company develops diagnostic tests, laboratory products, and related solutions that help customers detect foodborne pathogens, allergens, toxins, residues, and other contaminants throughout the food production process.

Its food safety portfolio includes test kits, culture media, molecular testing systems, sanitation monitoring products, and laboratory supplies used by food manufacturers, processors, retailers, and regulatory organizations.

Neogen (NEOG) Securities Investigation Notice - Levi & KorsinskyPR Newswire

NEW YORK, Oct. 7, 2026

Neogen shares fell 7.22% after an FDA warning concerning the recalled Neogen Vet product HYCOAT, which reporting tied to fungal contamination and at least 20 horse deaths.

, /PRNewswire/ -- Neogen (NASDAQ: NEOG) shares fell over 7% after an FDA warning concerning HYCOAT, a recalled Neogen Vet product that reporting linked to fungal contamination and at least 20 horse deaths. If you bought NEOG and are now holding losses, you have legal rights. Investors who lost money on Neogen are encouraged to submit their loss information now . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

FDA testing reportedly identified multiple fungal species in HYCOAT -- a product marketed as sterile. Coverage of the FDA action cited nearly 100 affected horses. The decline was reported by several financial news outlets, including Seeking Alpha, Benzinga, and TipRanks.

HYCOAT is sold under the Neogen Vet brand, part of the Company's Animal Safety segment, which generated $54.5 million in revenue in the third quarter of fiscal 2026. Reports to date have not quantified potential fines, litigation costs, or reserve impacts tied to the HYCOAT matter. The Levi & Korsinsky investigation concerns potential securities law violations related to these events.

If you purchased Neogen stock and suffered a loss, start your NEOG loss review today or call (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.

Frequently Asked Questions About the NEOG Investigation

Q: Who is conducting the NEOG investigation? A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased NEOG securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: Who is eligible to participate in the NEOG investigation? A: Investors who purchased NEOG stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did NEOG stock drop? A: Shares fell approximately 7.22% after an FDA warning concerning HYCOAT, a recalled Neogen Vet product that reporting linked to fungal contamination and at least 20 horse deaths. Investors who purchased shares and suffered losses may be eligible to seek recovery.

Q: What do NEOG investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What if I already sold my NEOG shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NEOG and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
[email protected] \
Tel: (212) 363-7500\
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neogen-neog-securities-investigation-notice---levi--korsinsky-302900725.html

SOURCE Levi & Korsinsky, LLP

Neogen shares fell 7.22% after an FDA warning concerning the recalled Neogen Vet product HYCOAT, which reporting tied to fungal contamination and at least 20 horse deaths.

, /PRNewswire/ -- Neogen (NASDAQ: NEOG) shares fell over 7% after an FDA warning concerning HYCOAT, a recalled Neogen Vet product that reporting linked to fungal contamination and at least 20 horse deaths. If you bought NEOG and are now holding losses, you have legal rights. Investors who lost money on Neogen are encouraged to submit their loss information now . You may also contact Joseph E. Levi, Esq. via email at [email protected]  or by telephone at (212) 363-7500.

FDA testing reportedly identified multiple fungal species in HYCOAT -- a product marketed as sterile. Coverage of the FDA action cited nearly 100 affected horses. The decline was reported by several financial news outlets, including Seeking Alpha, Benzinga, and TipRanks.

HYCOAT is sold under the Neogen Vet brand, part of the Company's Animal Safety segment, which generated $54.5 million in revenue in the third quarter of fiscal 2026. Reports to date have not quantified potential fines, litigation costs, or reserve impacts tied to the HYCOAT matter. The Levi & Korsinsky investigation concerns potential securities law violations related to these events.

If you purchased Neogen stock and suffered a loss, start your NEOG loss review today  or call (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP  -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.

Frequently Asked Questions About the NEOG Investigation

Q: Who is conducting the NEOG investigation?  A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased NEOG securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: Who is eligible to participate in the NEOG investigation?  A: Investors who purchased NEOG stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did NEOG stock drop?  A: Shares fell approximately 7.22% after an FDA warning concerning HYCOAT, a recalled Neogen Vet product that reporting linked to fungal contamination and at least 20 horse deaths. Investors who purchased shares and suffered losses may be eligible to seek recovery.

Q: What do NEOG investors need to do right now?  A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What is a lead plaintiff and why does it matter?  A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What if I already sold my NEOG shares -- can I still recover losses?  A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NEOG and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?  A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: What if I live outside the United States?  A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
[email protected] \
Tel: (212) 363-7500\
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE Levi & Korsinsky, LLP

Neogen NASDAQ: NEOG reported fiscal 2027 first-quarter revenue of $222.8 million, with core growth of 8.1%, as the company cited improved commercial execution, product-line strength in food safety and animal safety, and progress on its Petrifilm manufacturing transition.

Chief Executive Officer Mike Nassif said the quarter marked an acceleration from the prior quarter, though he noted that the timing of certain customer orders contributed to growth. The company is focusing its fiscal 2027 strategy on commercial execution, innovation and operational efficiency while continuing investments intended to support long-term growth and profitability.

Get Neogen alerts:

Revenue Growth Across Both Segments Food Safety revenue totaled $163.2 million, representing 8.1% core growth. Chief Financial Officer Bryan Riggsbee said first-quarter Food Safety growth received an approximately 400-basis-point benefit from order timing and a comparison to the prior-year period, when two large distributors made inventory adjustments.

Within Food Safety, indicator testing and culture media products, including Petrifilm, increased 11%. Bacterial and general sanitation products grew 7%, including double-digit growth in pathogen detection, Riggsbee said.

Animal Safety revenue was $59.6 million and rose 8% on a core basis, including roughly a 100-basis-point benefit from the timing of customer orders. The segment’s growth was driven by veterinary instruments, including needles and syringes supported by improved supply, as well as biosecurity products, particularly insect-control offerings.

Neogen generated growth in each geographic region, led by double-digit growth in Asia-Pacific. U.S. sales represented 49% of quarterly revenue, while international markets accounted for 51%.

During the question-and-answer session, Chief Commercial Officer Joe Freels said the company is working to increase its share of wallet with existing customers rather than relying primarily on new markets. He highlighted a new approach for global strategic accounts, under which a dedicated accountable leader is assigned to individual customers operating across multiple regions. Freels said those accounts grew 6.2% in the first quarter.

Margins, Cash Flow and Debt Neogen reported gross margin of 47.4% and adjusted gross margin of 49.8%, up 30 basis points from a year earlier on an adjusted basis. The adjusted margin improvement reflected higher revenue, partially offset by deliberate investments in operational excellence and inventory optimization.

Adjusted operating expenses were approximately flat year over year. Increased investment in research and development and general and administrative functions was offset by lower sales and marketing costs, including lower logistics and distribution expenses, centralized regional marketing resources and the divestiture of the cleaners and disinfectants business.

Adjusted EBITDA was $41.6 million, or 18.7% of revenue, representing 170 basis points of margin expansion. Adjusted net income was $17.5 million, and adjusted earnings per share were $0.08.

Free cash flow was $4.7 million, improving approximately $18 million from the prior-year quarter. Riggsbee attributed the improvement to higher operating cash flow and reduced capital expenditures as the company approaches completion of the Petrifilm manufacturing transition.

Neogen ended the quarter with about $774 million in debt and $172 million in cash. The company repaid $20 million of its term loan in June and another $10 million at the end of September. It remains compliant with its debt covenants, Riggsbee said.

Petrifilm Transfer and Innovation Initiatives The company said its planned multi-quarter transfer of Petrifilm manufacturing is expected to begin next month. Neogen has completed full validation of its first Petrifilm stock-keeping unit, confirming that the product met production, quality and stability requirements and performed equivalently to product made by its transition partner.

Nassif called the validation a “major de-risking milestone” for the program. He said Neogen is managing the transition around four priorities: customer continuity, safety-stock management, supplier management and disciplined sequencing across 17 SKUs.

Riggsbee said duplicative costs related to the transition are expected to peak and then decline as the transfer is completed. He said the company expects to begin implementing identified operational improvements during fiscal 2028 and anticipates 200 to 300 basis points of margin improvement in fiscal 2029.

Neogen also announced a strategic collaboration with Hinalea, a hyperspectral imaging company. Nassif said the technology could have applications across Food Safety and may help simplify customer workflows through faster detection and decision-making at processing sites.

Guidance Raised; Genomics Sale Still Under Review Neogen raised its fiscal 2027 revenue outlook to $885 million to $890 million and increased adjusted EBITDA guidance to $181 million to $183 million. The guidance continues to include the genomics business, which Neogen has agreed to divest.

The genomics transaction remains under review by regulatory authorities in Australia and New Zealand, with a final decision expected by the end of December. Neogen expects approximately $140 million in net proceeds, primarily for debt reduction. Riggsbee said the sale could reduce net leverage to below three times at closing and closer to 2.5 times by the end of the fiscal year.

The company expects first-half core growth of approximately 3.5%, noting that first-quarter results benefited from timing items and that the second quarter is expected to have the lowest core growth rate of the year. Neogen expects first-half adjusted EBITDA margin to be in line with the first quarter while it continues to invest in R&D, commercial infrastructure, technology and automation.

About Neogen (NASDAQ:NEOG)Neogen Corporation is a global provider of food safety and animal safety products and services. The company develops diagnostic tests, laboratory products, and related solutions that help customers detect foodborne pathogens, allergens, toxins, residues, and other contaminants throughout the food production process.

Its food safety portfolio includes test kits, culture media, molecular testing systems, sanitation monitoring products, and laboratory supplies used by food manufacturers, processors, retailers, and regulatory organizations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Neogen Right Now?Before you consider Neogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neogen wasn't on the list.

While Neogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

For the quarter ended August 2026, Neogen (NEOG - Free Report) reported revenue of $222.8 million, up 6.5% over the same period last year. EPS came in at $0.08, compared to $0.04 in the year-ago quarter.

The reported revenue represents a surprise of +7.07% over the Zacks Consensus Estimate of $208.09 million. With the consensus EPS estimate being $0.05, the EPS surprise was +60%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Neogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Food Safety: $163.2 million versus the two-analyst average estimate of $152.85 million. The reported number represents a year-over-year change of +7.3%.Revenues- Animal Safety: $59.6 million versus the two-analyst average estimate of $55.08 million. The reported number represents a year-over-year change of +4.3%.Revenues- Food Safety- Natural Toxins & Allergens: $19.3 million compared to the $20.15 million average estimate based on two analysts. The reported number represents a change of -3.3% year over year.Revenues- Food Safety- Bacterial & General Sanitation: $44.6 million versus $42.44 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.1% change.Revenues- Animal Safety- Genomics Services: $17.3 million compared to the $17.43 million average estimate based on two analysts. The reported number represents a change of +211.4% year over year.Revenues- Food Safety- Genomics Services: $6.7 million versus the two-analyst average estimate of $5.11 million. The reported number represents a year-over-year change of -59.6%.Revenues- Animal Safety- Life Sciences: $1.6 million versus the two-analyst average estimate of $1.92 million. The reported number represents a year-over-year change of -13.9%.Revenues- Animal Safety- Veterinary Instruments & Disposables: $14.1 million compared to the $11.55 million average estimate based on two analysts. The reported number represents a change of +18.4% year over year.Revenues- Animal Safety- Animal Care & Other: $7.7 million versus the two-analyst average estimate of $6.89 million. The reported number represents a year-over-year change of +1.6%.Revenues- Food Safety- Indicator Testing, Culture Media: $85.6 million versus the two-analyst average estimate of $80.8 million. The reported number represents a year-over-year change of +8.2%.View all Key Company Metrics for Neogen here>>>

Shares of Neogen have returned +10% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Neogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 29, 2026, the U.S. Food and Drug Administration (“FDA”) announced that it had issued a warning letter to Neogen “following an investigation that linked a veterinary wound care product labeled as sterile, Neogen Vet HYCOAT (hyaluronate sodium sterile solution), to serious infections and deaths in horses.”  The FDA said that “[t]his incident involved at least 20 horse deaths, making it the largest number of horse deaths ever associated with a quality defect in an FDA-regulated veterinary medical product and the most deaths of any animal species linked to microbiological contamination of an FDA-regulated product labeled as sterile” and further stated that “Neogen initiated a voluntary recall of HYCOAT in late January 2026.” 

On this news, Neogen’s stock price fell $0.99 per share, or 7.22%, to close at $12.73 per share on September 29, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

LANSING, Mich.--(BUSINESS WIRE)--Neogen® Corporation (NASDAQ: NEOG), a global leader in food safety solutions, is advancing its innovation strategy by combining deep food safety expertise with emerging technologies to introduce novel solutions to the Food Safety industry that address evolving customer challenges. As part of that strategy, Neogen today announced a strategic collaboration with and an equity investment in Hinalea Imaging Corp. to develop digital imaging solutions for food safety an.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neogen Corporation (“Neogen” or “the Company”) (NASDAQ: NEOG) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Neogen is the subject of an FDA warning letter issued on September 29, 2026, based on an investigation that linked the Company’s HYCOAT product to serious infections in almost 100 horses, including 20 that were euthanized as a result. Based on this news, shares of Neogen fell by 7.2%.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261004334718/en/

On October 01, 2026, Neogen Corp NEOG shares fell 4.4% to a current price of $12.24. This decline comes amid a challenging price performance, with the stock experiencing a 52-week high of $14.26 and a low of $5.37.

GF Value™ verdict: Current price $12.24 vs GF Value™ $11.19, indicating the stock is 9.4% overvalued.GF Score™ is 67/100, which reflects an above-average rating.Most notable signal: Insider activity shows no buying or selling, with insiders purchasing $0.0M in the past 12 months.Is NEOG Overvalued or Undervalued?Neogen Corp’s current price of $12.24 is above the GF Value™ estimate of $11.19, suggesting that the stock is overvalued by approximately 9.4%. This valuation discrepancy raises concerns regarding the stock's margin of safety, particularly in light of the company's unprofitable status. GF Value™ represents GuruFocus' proprietary intrinsic value estimate, derived from a combination of historical trading multiples, past growth metrics, and future performance projections. Given the loss-making nature of Neogen, the GF Value™ metric serves as a directional warning rather than a precise fair-value target.

The overvaluation risk is further underscored by the company's current cash-flow-negative status, which complicates traditional earnings-based valuation methods such as Price-to-Earnings (P/E) ratios. Instead, a Price-to-Sales (P/S) analysis becomes more relevant for assessing Neogen's valuation in the current environment.

How Does NEOG's Valuation Compare to Its History?MetricCurrentHistoricalP/E (TTM)Not applicable78.6xForward P/E41.4xNot availableNeogen Corp currently does not present a P/E ratio applicable for comparison, as the company is unprofitable. However, the forward P/E of 41.4x is substantially lower than its 5-year median P/E of 78.6x. This suggests that while the stock may be trading above GF Value™, the forward earnings potential could present a contrasting view on valuation. The P/E analysis aligns with the GF Value™ verdict indicating overvaluation, as it highlights the lack of profitability and the corresponding challenges in applying conventional valuation metrics.

What Does NEOG's GF Score™ Tell Us?The GF Score™ measures a stock's overall quality based on various factors including financial strength, profitability, growth potential, valuation, and momentum. Neogen Corp's score of 67/100 reveals that it is rated as above average, but with some weaknesses evident in certain areas such as growth.

MetricRatingGF Score™67/100Financial Strength4/10Profitability6/10Growth1/10Valuation6/10Momentum9/10Neogen's strongest area lies in its momentum rank of 9/10, indicating strong recent performance. However, the company faces significant challenges in growth, with a growth rank of just 1/10. This disparity highlights the potential volatility in the stock's performance, as the lack of growth could limit future upside despite positive momentum.

What Are Gurus and Insiders Doing with NEOG?Currently, five gurus hold Neogen Corp stock, with all five increasing their positions in recent quarters, while two have trimmed their holdings. This consistent interest from multiple gurus suggests a level of confidence in the stock's long-term potential, which is a noteworthy signal for investors.

On the insider activity front, there has been no recent buying or selling, with insiders purchasing $0.0M in the past year. This lack of insider activity may indicate a wait-and-see approach from those closest to the company, adding a layer of uncertainty amid the stock's current valuation issues.

What This Means for InvestorsBased on the analysis above, Neogen Corp appears to be overvalued with respect to its GF Value™ estimate. The stock's current price suggests it is trading at a premium, and potential investors should consider the inherent risks associated with investing in a loss-making company with limited growth prospects. For further details, you can visit the Neogen Corp NEOG stock page for comprehensive insights.

Frequently Asked QuestionsWhat is NEOG's GF Score™?

NEOG has a GF Score™ of 67/100, which indicates an above-average rating among stocks based on various fundamental metrics.

Is NEOG overvalued or undervalued?

NEOG is currently overvalued, with a GF Value™ estimate suggesting a 9.4% premium over its intrinsic value.

What is NEOG's P/E ratio?

Neogen does not have a applicable P/E ratio due to its unprofitable status; however, its forward P/E is 41.4x, which is significantly lower than its 5-year median of 78.6x.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

NEOG shares gave up as much as 7.22% on FDA action over the recalled HYCOAT equine product. The selloff came with no earnings report on the calendar until October 6.

, /PRNewswire/ -- Wiping out as much as 7.22% of its value, Neogen Corporation (NASDAQ: NEOG) stock sold off after the FDA took warning action concerning HYCOAT, a recalled Neogen Vet product for horses. If you bought NEOG shares and are now holding losses, you are encouraged to submit your NEOG loss information now . You may also contact Joseph E. Levi, Esq. via email at [email protected]  or by telephone at (888) SueWallSt.

No earnings report drove this move. Neogen's next quarterly report is scheduled for October 6, and no guidance change or consensus miss accompanied the decline. The Chronicle-Journal, TradingView, Seeking Alpha, TipRanks, and Benzinga each reported the selloff.

The trigger was the product itself. FDA testing reportedly identified multiple fungal species in HYCOAT, which was marketed as sterile. Coverage linked the product to nearly 100 affected horses and at least 20 horse deaths. None of the reporting quantified potential fines, litigation costs, or reserve impacts for Neogen. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of NEOG investors who suffered losses.

If NEOG's intraday selloff cut into your portfolio, have your NEOG losses reviewed today  or call Joseph E. Levi, Esq. at (888) SueWallSt.

WHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the NEOG Investigation

Q: How much did NEOG stock drop?  A: Shares fell approximately 7.22%, following FDA warning action concerning the recalled Neogen Vet product HYCOAT, which reporting linked to fungal contamination, nearly 100 affected horses, and at least 20 horse deaths. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?  A: The investigation concerns whether Neogen may have made materially false or misleading statements regarding product quality and its Animal Safety segment, including the Neogen Vet product line. When FDA action concerning the recalled HYCOAT product became public, the stock fell over 7%.

Q: When did Neogen allegedly mislead investors?  A: The investigation concerns statements made before the FDA action concerning HYCOAT became public that allegedly caused investors to purchase securities at inflated prices.

Q: What do NEOG investors need to do right now?  A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?  A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my NEOG shares -- can I still recover losses?  A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NEOG and sold at a loss may still participate in the investigation.

Q: Do I need to go to court or give testimony?  A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

Q: What does it cost me to participate?  A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected] 

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE SueWallSt.com

Wall Street analysts expect Neogen (NEOG - Free Report) to post quarterly earnings of $0.05 per share in its upcoming report, which indicates a year-over-year increase of 25%. Revenues are expected to be $208.09 million, down 0.5% from the year-ago quarter.

The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

In light of this perspective, let's dive into the average estimates of certain Neogen metrics that are commonly tracked and forecasted by Wall Street analysts.

The collective assessment of analysts points to an estimated 'Revenues- Food Safety- Natural Toxins & Allergens' of $20.15 million. The estimate indicates a year-over-year change of +0.9%.

Based on the collective assessment of analysts, 'Revenues- Food Safety- Bacterial & General Sanitation' should arrive at $42.44 million. The estimate indicates a change of +1.9% from the prior-year quarter.

The consensus estimate for 'Revenues- Food Safety- Indicator Testing, Culture Media & Other' stands at $80.80 million. The estimate points to a change of +2.2% from the year-ago quarter.

The consensus among analysts is that 'Revenues- Animal Safety- Veterinary Instruments & Disposables' will reach $11.55 million. The estimate points to a change of -3% from the year-ago quarter.

Analysts expect 'Revenues- Animal Safety- Animal Care & Other' to come in at $6.89 million. The estimate indicates a change of -9.1% from the prior-year quarter.

The combined assessment of analysts suggests that 'Revenues- Food Safety' will likely reach $152.85 million. The estimate points to a change of +0.5% from the year-ago quarter.

Analysts forecast 'Revenues- Animal Safety- Genomics Services' to reach $5.11 million. The estimate suggests a change of -69.2% year over year.

According to the collective judgment of analysts, 'Revenues- Food Safety- Genomics Services' should come in at $17.43 million. The estimate indicates a change of +213.8% from the prior-year quarter.

Analysts predict that the 'Revenues- Animal Safety' will reach $55.08 million. The estimate suggests a change of -3.6% year over year.

View all Key Company Metrics for Neogen here>>>

Over the past month, shares of Neogen have returned +8.4% versus the Zacks S&P 500 composite's -0.4% change. Currently, NEOG carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON NEOGEN CORPORATION (NEOG), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On September 29, 2026, the FDA announced it had issued a warning letter to Neogen, following an investigation that linked a Neogen’s Hycoat product “to serious infections and deaths in horses.” The FDA stated the “incident involved at least 20 horse deaths, making it the largest number of horse deaths ever associated with a quality defect in an FDA-regulated veterinary medical product and the most deaths of any animal species linked to microbiological contamination of an FDA-regulated product labeled as sterile. The FDA also reviewed Hycoat’s labeling and determined that the product is also misbranded “because its labeling fails to bear adequate directions for use.”

On this news, Neogen stock fell $0.99 or 7.22%, to close at $12.73 on September 29, 2026.

Contact Us To Participate or Learn More:

If you purchased Neogen Corporation securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [email protected]
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

More News From The Law Offices of Frank R. Cruz

Neogen Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Neogen (NEOG)PR Newswire

NEW YORK, Sept. 30, 2026

An FDA warning over the recalled HYCOAT equine product cut as much as 7.22% from NEOG in a single session. The investigation concerns whether Neogen investors were adequately informed of Neogen Vet product-quality risks before the news reached the market.

, /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) stock plummeted after an FDA warning concerning the recalled Neogen Vet product HYCOAT sent shares down as much as 7.22%. If you owned NEOG when that warning hit the market, you may have legal rights. Investors who lost money are encouraged to submit their loss details now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

HYCOAT was marketed as sterile. FDA testing reportedly identified multiple fungal species in the product, and coverage of the warning cited nearly 100 affected horses and at least 20 horse deaths.

The decline came before any earnings report. Neogen's next quarterly results are not scheduled until October 6, 2026. Levi & Korsinsky is investigating potential securities law violations on behalf of Neogen shareholders who suffered losses, including those who have since sold their shares.

Neogen shareholders who suffered a loss can request a review of their NEOG losses or call (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the NEOG Investigation

Q: How much did NEOG stock drop?A: Shares fell as much as approximately 7.22% intraday after an FDA warning concerning the recalled Neogen Vet product HYCOAT, which reporting tied to fungal contamination, nearly 100 affected horses, and at least 20 horse deaths. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Neogen made materially false or misleading statements about the quality, supply, and performance of its Animal Safety products, including the Neogen Vet product line. When the FDA warning concerning the recalled HYCOAT product became public, the stock price declined.

Q: When did Neogen allegedly mislead investors?A: The investigation concerns statements made before the FDA warning regarding HYCOAT that allegedly caused investors to purchase securities at inflated prices.

Q: What do NEOG investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my NEOG shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NEOG and sold at a loss may still participate in the investigation.

Q: What if my NEOG losses are small -- is it still worth contacting a lawyer?A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neogen-investigation-notice-levi--korsinsky-notifies-investors-of-pending-investigation-into-neogen-neog-302894735.html

SOURCE Levi & Korsinsky, LLP

Neogen Corporation (NASDAQ:NEOG) will release earnings for its first quarter after the closing bell on Tuesday, Oct. 6.

Analysts expect the Lansing, Michigan-based company to report quarterly earnings of 5 cents per share, up from 4 cents per share in the year-ago period. The consensus estimate for Neogen’s quarterly revenue is $208.18 million. It reported $209.19 million last year, according to Benzinga Pro.

On July 30, Neogen reported better-than-expected fourth-quarter financial results.

Shares of Neogen rose 0.7% to close at $13.66 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Piper Sandler analyst David Westenberg upgraded the stock from Neutral to Overweight and raised the price target from $13 to $14 on Aug. 26, 2026. This analyst has an accuracy rate of 75%. Guggenheim analyst Subbu Nambi maintained a Buy rating and boosted the price target from $8 to $12 on Jan. 9, 2026. This analyst has an accuracy rate of 80%. CJS Securities analyst Robert Labick upgraded the stock from Market Perform to Market Outperform with a price target of $10 on Dec. 10, 2025. This analyst has an accuracy rate of 71%. Considering buying NEOG stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Key Takeaways Neogen is expanding its pipeline with new products and plans to raise fiscal 2027 R&D spending by 50%.NEOG expects in-house Petrifilm production to begin in November 2026, supporting more product innovation.NEOG's Animal Safety supply issues eased, while $140 million of Genomics proceeds may reduce debt. Neogen Corporation (NEOG - Free Report) is advancing its product development efforts across food and animal safety, supported by increased investment in innovation. The company is building on its 3M Food Safety combination to expand manufacturing capacity and pursue new product opportunities. Animal Safety showed a sharper recovery in the fourth quarter of fiscal 2026 as supplier issues eased and product availability improved. Meanwhile, Neogen’s financial position remains pressured by high debt, while intense competition is also a risk.

Over the past year, this Zacks Rank #2 (Buy) stock has surged 107.7% against the 29.3% fall of the industry and the S&P 500’s 17.5% rise.

The renowned food and animal safety product provider has a market capitalization of $2.59 billion. Neogen surpassed earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 57%. 

Let’s delve deeper.

NEOG: Factors at PlayProduct Launches: Neogen is expanding its food and animal safety pipeline with new products while shifting more resources toward differentiated technologies. Recent additions include Neogen MPNTray, the Listeria Right Now molecular detection assay, Igenity BCHF and MDA2 Quantitative Salmonella. Listeria Right Now earned AOAC Performance Tested Methods certification in fiscal 2026, supporting broader commercial use of the enrichment-free environmental monitoring test.

Management expects to raise fiscal 2027 R&D spending by about 50%, with investments spanning Petrifilm innovation, digital connectivity, licensed technologies and next-generation pathogen detection and sanitation platforms. Neogen expects the organic development cycle to take 18 to 24 months and plans multiple Petrifilm SKU launches as its in-house manufacturing capabilities expand.

Image Source: Zacks Investment Research

3M Integration Expands Opportunity: The 2022 combination with 3M’s Food Safety business continues to strengthen Neogen’s product breadth and manufacturing capabilities, with Petrifilm playing a key role. Neogen is bringing Petrifilm manufacturing in-house at its Lansing facility and expects to complete validation of the first SKU by the end of August 2026.

Sellable production and a multi-quarter manufacturing transition are expected to begin in November 2026. As the transfer moves forward, management expects duplicate manufacturing costs to decline, with benefits from the transition starting in the following fiscal year. The new platform is designed to accommodate further Petrifilm innovation, along with expansion into pharmaceuticals, nutraceuticals and consumer products. Neogen expects to launch at least two Petrifilm SKUs annually through the new process and has identified at least five candidates. These capabilities could extend the acquired platform beyond its original food and beverage testing base.

Animal Safety Supply Recovery: Neogen’s Animal Safety business entered fiscal 2027 with most of the third-party supplier issues that disrupted fiscal 2026 resolved. Fourth-quarter fiscal 2026 revenues fell 8.2% year over year, while core revenues rose 0.5% and sales increased more than 7% sequentially. The improvement followed an 8.7% core decline in the third quarter as product availability began to normalize.

Management also cited improving production animal markets, with higher meat prices supporting producer profitability and U.S. herd sizes showing signs of stabilization. Commercial resources are focused on priority products and accounts, while supplier qualification and quality processes are being tightened. Animal Safety is expected to grow more slowly than Food Safety in fiscal 2027, but the restored supply base and favorable end-market backdrop should support a more stable medium-term trajectory.

What Ails Neogen?Weak Solvency: Neogen ended fiscal 2026 with $185.5 million in cash against about $800 million in debt. It repaid $20 million after year-end and plans to use roughly $140 million of expected net Genomics proceeds primarily for debt reduction, leaving deleveraging dependent on closing.

Tough Competitive Landscape: Neogen faces intense competition from companies ranging from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, Neogen has faced intense competition resulting from the development of new technologies by competitors, which could affect the marketability and profitability of its products.

NEOG Stock’s Estimate TrendIn the past 30 days, the Zacks Consensus Estimate for Neogen’s earnings for fiscal 2027 has risen 3.3% to 31 cents.

The consensus mark for fiscal 2027 revenues is pegged at $883.2 million, which suggests a 1.5% rise from the prior year.

Other Key PicksSome other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Teleflex (TFX - Free Report) .

Veracyte has an earnings yield of 4.5% against the industry’s negative 1.3% yield. Shares of the company have risen 42.3% against the industry’s 5% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6% against the industry’s negative 1.3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.5% against the industry’s 5% drop over the past year.

Teleflex, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.9% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4.2% against the industry’s 5% decline over the past year.

Corient Private Wealth LP acquired a new stake in shares of Neogen Corporation (NASDAQ:NEOG – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 46,234 shares of the company’s stock, valued at approximately $416,000.

Other hedge funds have also made changes to their positions in the company. BlackRock Inc. acquired a new stake in Neogen in the 2nd quarter worth approximately $300,545,000. Dimensional Fund Advisors LP grew its holdings in Neogen by 23.4% during the first quarter. Dimensional Fund Advisors LP now owns 9,132,021 shares of the company’s stock valued at $84,831,000 after purchasing an additional 1,733,767 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Neogen by 249.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 8,181,768 shares of the company’s stock valued at $57,191,000 after purchasing an additional 5,838,570 shares during the last quarter. Mackenzie Financial Corp raised its position in shares of Neogen by 1.0% in the fourth quarter. Mackenzie Financial Corp now owns 7,898,439 shares of the company’s stock valued at $55,574,000 after purchasing an additional 79,010 shares during the period. Finally, Cibc World Markets Corp bought a new position in shares of Neogen in the fourth quarter valued at approximately $47,983,000. Institutional investors and hedge funds own 96.73% of the company’s stock.

Wall Street Analyst Weigh In NEOG has been the subject of a number of analyst reports. Piper Sandler upgraded shares of Neogen from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $13.00 to $14.00 in a research note on Wednesday, August 26th. Weiss Ratings upgraded shares of Neogen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $12.00.

Read Our Latest Stock Analysis on Neogen Neogen Price Performance Shares of NASDAQ:NEOG opened at $11.83 on Tuesday. The business has a 50 day moving average price of $10.77 and a 200 day moving average price of $9.90. Neogen Corporation has a twelve month low of $4.90 and a twelve month high of $12.85. The company has a market cap of $2.58 billion, a price-to-earnings ratio of -394.33, a PEG ratio of 4.44 and a beta of 1.76. The company has a quick ratio of 2.91, a current ratio of 3.82 and a debt-to-equity ratio of 0.38.

Neogen (NASDAQ:NEOG – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.06 by $0.03. Neogen had a positive return on equity of 2.78% and a negative net margin of 0.91%.The company had revenue of $225.30 million for the quarter, compared to the consensus estimate of $212.35 million. During the same period in the previous year, the business posted ($2.82) EPS. The company’s revenue for the quarter was down .1% on a year-over-year basis. Research analysts predict that Neogen Corporation will post 0.27 earnings per share for the current year.

Neogen Company Profile (Free Report)

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.

See Also Five stocks we like better than Neogen 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding NEOG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neogen Corporation (NASDAQ:NEOG – Free Report).

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Neogen (NEOG - Free Report) , which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Neogen currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for NEOG that show why this maker of medical testing kits shows promise as a solid momentum pick.

A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.

For NEOG, shares are up 2.58% over the past week while the Zacks Medical - Products industry is flat over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 27.13% compares favorably with the industry's 5.26% performance as well.

Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Shares of Neogen have increased 33.22% over the past quarter, and have gained 111.88% in the last year. On the other hand, the S&P 500 has only moved 3.37% and 21.73%, respectively.

Investors should also pay attention to NEOG's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. NEOG is currently averaging 2,382,204 shares for the last 20 days.

Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with NEOG.

Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. This revision helped boost NEOG's consensus estimate, increasing from $0.28 to $0.30 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period.

Bottom LineTaking into account all of these elements, it should come as no surprise that NEOG is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Neogen on your short list.